[HTML][HTML] B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study

BF Haynes, G Kelsoe, SC Harrison, TB Kepler - Nature biotechnology, 2012 - nature.com
BF Haynes, G Kelsoe, SC Harrison, TB Kepler
Nature biotechnology, 2012nature.com
Failure of immunization with the HIV-1 envelope to induce broadly neutralizing antibodies
against conserved epitopes is a major barrier to producing a preventive HIV-1 vaccine.
Broadly neutralizing monoclonal antibodies (BnAbs) from those subjects who do produce
them after years of chronic HIV-1 infection have one or more unusual characteristics,
including polyreactivity for host antigens, extensive somatic hypermutation and long,
variable heavy-chain third complementarity-determining regions, factors that may limit their …
Abstract
Failure of immunization with the HIV-1 envelope to induce broadly neutralizing antibodies against conserved epitopes is a major barrier to producing a preventive HIV-1 vaccine. Broadly neutralizing monoclonal antibodies (BnAbs) from those subjects who do produce them after years of chronic HIV-1 infection have one or more unusual characteristics, including polyreactivity for host antigens, extensive somatic hypermutation and long, variable heavy-chain third complementarity-determining regions, factors that may limit their expression by host immunoregulatory mechanisms. The isolation of BnAbs from HIV-1–infected subjects and the use of computationally derived clonal lineages as templates provide a new path for HIV-1 vaccine immunogen design. This approach, which should be applicable to many infectious agents, holds promise for the construction of vaccines that can drive B cells along rare but desirable maturation pathways.
nature.com